Occurrence of abscesses during treatment with pazopanib in metastatic renal cancer: a case report
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1752-1947
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Occurrence of abscesses during treatment with pazopanib in metastatic renal cancer: a case report ; volume:14 ; number:1 ; day:11 ; month:1 ; year:2020 ; pages:1-3 ; date:12.2020
Journal of medical case reports ; 14, Heft 1 (11.1.2020), 1-3, 12.2020
- Urheber
-
Puliafito, Ivana
Russo, Alessio
Sciacca, Dorotea
Puglisi, Caterina
Giuffrida, Dario
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13256-019-2318-y
- URN
-
urn:nbn:de:101:1-2020041500444277154090
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:53 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Puliafito, Ivana
- Russo, Alessio
- Sciacca, Dorotea
- Puglisi, Caterina
- Giuffrida, Dario
- SpringerLink (Online service)
Ähnliche Objekte (12)
Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib
Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?
Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report
Pazopanib after Nivolumab-Induced Tumor Lysis Syndrome in a Patient with Metastatic Clear-Cell Renal Cell Carcinoma
Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial
Durable Response to Pazopanib in Recurrent Metastatic Carotid Body Paraganglioma
Pazopanib-induced enteritis in a patient with renal cell carcinoma
Eight years tumor control with pazopanib for a metastatic resistant epithelioid hemangioendothelioma
First‐line pazopanib in intermediate‐ and poor‐risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial
Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network
A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma
Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors
Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib
Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?
Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report
Pazopanib after Nivolumab-Induced Tumor Lysis Syndrome in a Patient with Metastatic Clear-Cell Renal Cell Carcinoma
Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial
Durable Response to Pazopanib in Recurrent Metastatic Carotid Body Paraganglioma
Pazopanib-induced enteritis in a patient with renal cell carcinoma
Eight years tumor control with pazopanib for a metastatic resistant epithelioid hemangioendothelioma
First‐line pazopanib in intermediate‐ and poor‐risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial
Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network
A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma
Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors
Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib
Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?
Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report
Pazopanib after Nivolumab-Induced Tumor Lysis Syndrome in a Patient with Metastatic Clear-Cell Renal Cell Carcinoma
Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial
Durable Response to Pazopanib in Recurrent Metastatic Carotid Body Paraganglioma
Pazopanib-induced enteritis in a patient with renal cell carcinoma
Eight years tumor control with pazopanib for a metastatic resistant epithelioid hemangioendothelioma
First‐line pazopanib in intermediate‐ and poor‐risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial
Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network
A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma